DENVER, March 17, 2025
Recent clinical data demonstrate how HepQuant DuO test results may be used to inform endoscopy screening decisions, monitor disease progression and evaluate response to resmetirom therapy in patients with compensated advanced chronic liver disease (cACLD). Eight abstracts will be presented at the 2025 Global Hepatitis Summit, Liver Connect 2025, EASL 2025, and DDW 2025 conferences. HepQuant DuO is a minimally invasive blood test to quantify liver health and enable liver specialists to enhance patient management.
Advertisement
DENVER, March 17, 2025 /PRNewswire-PRWeb/ -- HepQuant, LLC continues to expand clinical availability of the HepQuant DuO test to liver specialists in clinical practice, and will present eight abstracts at key upcoming liver conferences, including the 2025 Global Hepatitis Summit in Los Angeles, CA, Liver Connect 2025 in San Antonio, TX, EASL 2025 in Amsterdam, NL, and DDW 2025 in San Diego, CA. These important findings highlight the utility of HepQuant DuO in assessing liver health by quantifying liver function and physiology in patients with Compensated Advanced Chronic Liver Disease (cACLD). The test reports the risk of large esophageal varices (LEV's) and a Disease Severity Index (DSI) risk score to inform the decision to avoid or proceed with endoscopic screening.
Advertisement
Other HepQuant DuO test results include a Hepatic Reserve (HR%) to measure a patient's current level of liver impairment and a SHUNT% to further evaluate risk of LEV's, other clinical outcomes and portal systemic shunting. Healthcare providers may use these results to make patient management decisions and to advise their patients in making changes to improve their liver health. To date, HepQuant has published 16 studies supporting the clinical validity and utility of HepQuant DuO testing for patients with cACLD, including those diagnosed with compensated Child-Pugh A cirrhosis, advanced fibrosis, and those suspected of having portal hypertension and varices.
Nationally recognized liver specialists and the HepQuant team will also present the following abstracts and posters to liver specialists at the 2025 Global Hepatitis Summit, Liver Connect, EASL, and DDW conferences.
2025 Global Hepatitis Summit (March 18-21)
Liver Connect 2025 (March 20-22)
DDW 2025 (May 3-6)
EASL 2025 (May 7-10)
Media Contact
Joellyn Enos, HepQuant, LLC, 1 303-268-7069, joellyn.enos@hepquant.com, https://hepquant.com/
Twitter, LinkedIn
View original content to download multimedia:https://www.prweb.com/releases/hepquant-to-present-at-key-liver-conferences-to-highlight-applications-of-hepquant-duo--a-quantitative-liver-health-test-302402791.html
SOURCE HepQuant, LLC
